Maa: Kanada
Kieli: englanti
Lähde: Health Canada
CANDESARTAN CILEXETIL
LABORATOIRE RIVA INC.
C09CA06
CANDESARTAN
32MG
TABLET
CANDESARTAN CILEXETIL 32MG
ORAL
30/100
Prescription
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Active ingredient group (AIG) number: 0135220004; AHFS:
CANCELLED POST MARKET
2019-04-01
_RIVA-CANDESARTAN Product Monograph_ _Page 1 of 38_ PRODUCT MONOGRAPH PR RIVA-CANDESARTAN Candesartan cilexetil tablets 4 mg, 8 mg, 16 mg and 32 mg ANGIOTENSIN II AT 1 RECEPTOR BLOCKER LABORATOIRE RIVA INC. 660 Boul. Industriel Blainville, Québec J7C 3V4 www.labriva.com DATE OF REVISION : October 17, 2016 Submission Control No: 198061 _RIVA-CANDESARTAN Product Monograph_ _Page 2 of 38_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ....................................................... 3 SUMMARY PRODUCT INFORMATION ........................................................................ 3 INDICATIONS AND CLINICAL USE .............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 4 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................... 8 DRUG INTERACTIONS .................................................................................................. 14 DOSAGE AND ADMINISTRATION ............................................................................. 16 OVERDOSAGE ................................................................................................................ 19 ACTION AND CLINICAL PHARMACOLOGY ............................................................ 19 STORAGE AND STABILITY ......................................................................................... 22 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................. 22 PART II: SCIENTIFIC INFORMATION ............................................................................. 23 PHARMACEUTICAL INFORMATION ......................................................................... 23 CLINICAL TRIALS ............................................................................................ Lue koko asiakirja